NCT00237172已完成2 期
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 72
- 主要终点
- To study the antineoplastic effect of the investigational drug.
研究概览
简要总结
This is a extension study of CSTI571B1201 study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who completed the CSTI571B1201 study
排除标准
- •Other protocol-defined inclusion / exclusion criteria may apply.
研究组 & 干预措施
Imatinib Mesylate
Experimental
400 mg once daily
干预措施: Imatinib Mesylate (Drug)
结局指标
主要结局
To study the antineoplastic effect of the investigational drug.
次要结局
- To study the safety and pharmacokinetics of the investigational drug.
研究者
相似试验
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryAcral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT00470470National Cancer Institute (NCI)30
已完成
2 期
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansDermatofibrosarcoma ProtuberansAdult FibrosarcomaRecurrent Adult Soft Tissue SarcomaStage IV Adult Soft Tissue SarcomaNCT00084630National Cancer Institute (NCI)40
已完成
2 期
Imatinib Mesylate in Treating Patients With Recurrent MeningiomaAdult Grade I MeningiomaAdult Grade II MeningiomaAdult Grade III MeningiomaAdult Meningeal HemangiopericytomaAdult MeningiomaRecurrent Adult Brain TumorNCT00045734National Cancer Institute (NCI)23
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial CancerNCT00036751National Cancer Institute (NCI)40
已完成
2 期
Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentEsophageal Squamous Cell CarcinomaNCT02976896Yuhong Li43